Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 26 (2), 144-53

Prevention and Treatment Strategies for Glucocorticoid-Induced Osteoporotic Fractures

Affiliations
Review

Prevention and Treatment Strategies for Glucocorticoid-Induced Osteoporotic Fractures

Margaret Gourlay et al. Clin Rheumatol.

Abstract

Glucocorticoids are the most common cause of drug-related osteoporosis. We reviewed current evidence on risk factors for glucocorticoid-induced osteoporosis (GIOP) and prevention and treatment of GIOP-related fractures. Guidelines for GIOP management published since 2000 were also reviewed. Significant bone loss and increased fracture risk is seen with daily prednisone doses as low as 5 mg. Alternate-day glucocorticoid therapy can lead to similar bone loss. No conclusive evidence exists for a safe minimum dose or duration of glucocorticoid exposure. Physicians should consider risk factors for involutional osteoporosis such as older age, postmenopausal status, and baseline bone density measurements as they assess patients for prevention or treatment of GIOP. Bisphosphonates were reported to reduce GIOP-related vertebral fractures, but inconclusive data exist for hip fractures associated with glucocorticoid use. Hormone replacement therapy and parathyroid hormone analogs are effective in preserving bone density in GIOP. The risk of osteoporosis and fractures should be routinely assessed in patients receiving glucocorticoid therapy. Effective prevention and treatment options are available and can result in meaningful reduction of GIOP-related morbidity and mortality. Current guidelines for GIOP management recommend bisphosphonates, especially alendronate and risedronate, as first-line agents for GIOP, and these guidelines propose the preventive use of bisphosphonates early in the course of glucocorticoid therapy in high-risk patient subgroups.

Similar articles

See all similar articles

Cited by 8 PubMed Central articles

See all "Cited by" articles

References

    1. J Bone Miner Metab. 2005;23(2):105-9 - PubMed
    1. Thorax. 2004 Sep;59(9):761-8 - PubMed
    1. J Rheumatol. 2000 Jul;27(7):1759-65 - PubMed
    1. Am J Med. 1994 Feb;96(2):115-23 - PubMed
    1. J Clin Endocrinol Metab. 1998 Apr;83(4):1128-33 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

Feedback